ATL's HDI Digital Ultrasound Is Approved for Breast Indication

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

BOTHELL, Wash--A High Definition Imaging (HDI) digital ultrasound system from Advanced Technology Laboratories (ATL) has been granted FDA approval for a new indication--adjuvant use with mammog-raphy and physical examination to help physicians determine if a biopsy is necessary after discovery of a suspicious breast lesion.

BOTHELL, Wash--A High Definition Imaging (HDI) digital ultrasoundsystem from Advanced Technology Laboratories (ATL) has been grantedFDA approval for a new indication--adjuvant use with mammog-raphyand physical examination to help physicians determine if a biopsyis necessary after discovery of a suspicious breast lesion.

The indication for the Ultramark 9 HDI system is based on thefindings of an international multicenter study involving morethan 1,000 women with breast lesions who were undergoing breastbiopsy.

Lesions were classified based on mammography results, then reclassifiedafter an HDI ultrasound examination performed before breast biopsy.

Investigators found that the number of biopsies could be reducedby approximately 40% using ATL's HDI ultrasound system to distinguishbenign from malignant lesions that were indeterminate by mammographyand physical examination.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content